Nature Communications (May 2020)

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

  • Eugenia Zah,
  • Eunwoo Nam,
  • Vinya Bhuvan,
  • Uyen Tran,
  • Brenda Y. Ji,
  • Stanley B. Gosliner,
  • Xiuli Wang,
  • Christine E. Brown,
  • Yvonne Y. Chen

DOI
https://doi.org/10.1038/s41467-020-16160-5
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 13

Abstract

Read online

One cause of relapse in cancer patients treated with chimeric antigen receptor (CAR) T cells is the loss of CAR-targeted antigens, which is particularly common in multiple myeloma (MM). Here the authors engineer a CAR recognizing two common MM-associated antigens and demonstrate its superiority to single-antigen CARs in a mouse model of MM.